Transaction #20102 · Form 4 · 0001822557-25-000007
SPRUCE BIOSCIENCES, INC. · Stock award · Stock Option (Right to Buy)
SPRUCE BIOSCIENCES, INC. · Transacted December 11, 2025 · Filed December 15, 2025
What does this filing report?
An SEC Form 4 filing for SPRUCE BIOSCIENCES, INC. records a stock award involving Stock Option (Right to Buy) on December 11, 2025. The reported quantity was 362. The filing date is December 15, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- SPRUCE BIOSCIENCES, INC.
- Company CIK
- 0001683553
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 362
- Reported price
- Not reported · See footnotes
- Reference value
- Not reported
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 362
- Ownership description
- Not reported
- SEC acceptance time
- Dec 15, 2025, 6:50 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- SIMPSON CAMILLA V ↗
Director
CIK 0001822557
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 362
- Conversion / exercise price
- 104.13
- Exercise date
- Not reported
- Expiration date
- August 6, 2030
Filing footnotes & remarks
- F1
- Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five.
- F2
- The shares subject to the option are fully vested and exercisable.
- F3
- The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date.
- F4
- Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.